UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A 1‐minute full brain MR exam using a multicontrast EPI sequence

Magnetic resonance in medicine, 2018-06, Vol.79 (6), p.3045-3054

2018

Volltextzugriff (PDF)

10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents

Journal of the American College of Cardiology, 2017-02, Vol.69 (6), p.616-624

2017

Volltextzugriff (PDF)

The 2p 3 3s, 3p and 3d configurations of eight times ionized sulphur, S IX

Physica scripta, 1997-12, Vol.56 (6), p.592-598

1997

Volltextzugriff (PDF)

The 2p33s, 3p and 3d configurations of eight times ionized sulphur, S IX

Physica scripta, 1997-12, Vol.56, p.592

1997

Volltextzugriff (PDF)

A1.1 Characterisation of lung inflammation and identification of shared citrullinated targets in the lungs and joints of early rheumatoid arthritis

Annals of the rheumatic diseases, 2014-03, Vol.73 (Suppl 1), p.A4-A5

2014

Volltextzugriff (PDF)

A1.4 Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs

Annals of the rheumatic diseases, 2013-03, Vol.72 (Suppl 1), p.A2-A2

2013

Volltextzugriff (PDF)

A1166 Use of proteomics to investigate blood pressure progress in the elderly

Journal of hypertension, 2018-10, Vol.36 Suppl 3, p.e115-e115

2018

Volltextzugriff (PDF)

Abdominal massage for people with constipation: a cost utility analysis

Journal of advanced nursing, 2010-08, Vol.66 (8), p.1719-1729

2010

Volltextzugriff (PDF)

Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas

International journal of oncology, 2004-11, Vol.25 (5), p.1349

2004

Volltextzugriff (PDF)

Abstract 10885: SCORE Estimated Risk is Associated With Prevalent Subclinical Atherosclerosis in a Swedish Population Without Cardiovascular Disease or Diabetes

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A10885-A10885

2018

Volltextzugriff (PDF)

Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1131-1131

2022

Volltextzugriff (PDF)

Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1212-1212

2024

Volltextzugriff (PDF)

Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.130-130

2015

Volltextzugriff (PDF)

Abstract 17573: Exenatide for Neuroprotection After Out-of-Hospital Cardiac Arrest, a Double-blind Randomized Controlled Trial

Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A17573-A17573

2016

Volltextzugriff (PDF)

Abstract 2642: Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2642-2642

2016

Volltextzugriff (PDF)

Abstract 2664: Clinical Outcome and Left Ventricular Contractile Function After Distal Protection in Primary Percutaneous Coronary Intervention The Drug Elution and Distal Protection in ST-Elevation Myocardial Infarction (DEDICATION) Trial

Circulation (New York, N.Y.), 2008-10, Vol.118 (suppl_18)

2008

Volltextzugriff (PDF)

Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2778-2778

2023

Volltextzugriff (PDF)

Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2779-2779

2023

Volltextzugriff (PDF)

Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del, KRAS -mutant cancers

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3319-3319

2024

Volltextzugriff (PDF)

Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3499-3499

2023

Volltextzugriff (PDF)

Abstract 4021: The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4021-4021

2016

Volltextzugriff (PDF)

Abstract 4464: Elucidation of crizotinib resistance in NCI-H3122 and strategies to circumvent bypass resistance

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4464-4464

2013

Volltextzugriff (PDF)

Abstract 4482: Novel and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 inhibit the PDK-1/AKT signaling pathway and cell proliferation

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4482-4482

2010

Volltextzugriff (PDF)

Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4504-4504

2011

Volltextzugriff (PDF)

Abstract 5684: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5684-5684

2020

Volltextzugriff (PDF)

1 – 25 von 927

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(864)
Mit Volltextzugriff
(800)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(597)
Life Sciences & Biomedicine
(515)
Humans
(449)
Male
(332)
Female
(301)
Middle Aged
(295)
Medicin Och Hälsovetenskap
(269)
Aged
(198)
Adult
(177)
Medical And Health Sciences
(177)
Cardiovascular System & Cardiology
(174)
Biological And Medical Sciences
(151)
Clinical Medicine
(145)
Klinisk Medicin
(145)
Cardiac & Cardiovascular Systems
(140)
Medical Sciences
(134)
Risk Factors
(118)
Cardiac And Cardiovascular Systems
(102)
Kardiologi
(102)
Medicine
(87)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

A 1‐minute full brain MR exam using a multicontrast EPI sequence

10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents

The 2p 3 3s, 3p and 3d configurations of eight times ionized sulphur, S IX

The 2p33s, 3p and 3d configurations of eight times ionized sulphur, S IX

A1.1 Characterisation of lung inflammation and identification of shared citrullinated targets in the lungs and joints of early rheumatoid arthritis

A1.4 Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs

A1166 Use of proteomics to investigate blood pressure progress in the elderly

Abdominal massage for people with constipation: a cost utility analysis

Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas

Abstract 10885: SCORE Estimated Risk is Associated With Prevalent Subclinical Atherosclerosis in a Swedish Population Without Cardiovascular Disease or Diabetes

Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models

Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models

Abstract 17573: Exenatide for Neuroprotection After Out-of-Hospital Cardiac Arrest, a Double-blind Randomized Controlled Trial

Abstract 2642: Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models

Abstract 2664: Clinical Outcome and Left Ventricular Contractile Function After Distal Protection in Primary Percutaneous Coronary Intervention The Drug Elution and Distal Protection in ST-Elevation Myocardial Infarction (DEDICATION) Trial

Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers

Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers

Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del, KRAS -mutant cancers

Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC

Abstract 4021: The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations

Abstract 4464: Elucidation of crizotinib resistance in NCI-H3122 and strategies to circumvent bypass resistance

Abstract 4482: Novel and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 inhibit the PDK-1/AKT signaling pathway and cell proliferation

Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models

Abstract 5684: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models

Aktive Filter

Suchergebnisse filtern